INmune Bio: CORDStrom MAA mid-2026, XPro Phase 3 in 2027; $30M cash as of Oct 14

Inmune Bio, Inc.

CORDStrom Phase 2 in RDEB improves itch/pain; MAA to UK MHRA mid-2026, BLA in US late-2026.
XPro1595 Phase 2 in early AD halts cognitive decline in biomarker-enriched patients; zero ARIA cases.
End-of-Phase-2 FDA meeting for XPro in Q1 2026; Phase 3 start planned for 2027.
Cash $30M as of Oct 14, 2025; market cap ~$50M; ~26.5M shares outstanding.
CORDStrom has Rare Pediatric Disease and Orphan Drug designations; potential PRV.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.